IBDEI2GQ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41322,2)
 ;;=^5007823
 ;;^UTILITY(U,$J,358.3,41323,0)
 ;;=I80.11^^189^2094^7
 ;;^UTILITY(U,$J,358.3,41323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41323,1,3,0)
 ;;=3^Phlebitis & Thromboph,Right Femoral Vein
 ;;^UTILITY(U,$J,358.3,41323,1,4,0)
 ;;=4^I80.11
 ;;^UTILITY(U,$J,358.3,41323,2)
 ;;=^5007825
 ;;^UTILITY(U,$J,358.3,41324,0)
 ;;=I80.12^^189^2094^5
 ;;^UTILITY(U,$J,358.3,41324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41324,1,3,0)
 ;;=3^Phlebitis & Thromboph,Left Femoral Vein
 ;;^UTILITY(U,$J,358.3,41324,1,4,0)
 ;;=4^I80.12
 ;;^UTILITY(U,$J,358.3,41324,2)
 ;;=^5007826
 ;;^UTILITY(U,$J,358.3,41325,0)
 ;;=I80.13^^189^2094^3
 ;;^UTILITY(U,$J,358.3,41325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41325,1,3,0)
 ;;=3^Phlebitis & Thromboph,Bilateral Femora Vein
 ;;^UTILITY(U,$J,358.3,41325,1,4,0)
 ;;=4^I80.13
 ;;^UTILITY(U,$J,358.3,41325,2)
 ;;=^5007827
 ;;^UTILITY(U,$J,358.3,41326,0)
 ;;=L98.0^^189^2094^21
 ;;^UTILITY(U,$J,358.3,41326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41326,1,3,0)
 ;;=3^Pyogenic granuloma
 ;;^UTILITY(U,$J,358.3,41326,1,4,0)
 ;;=4^L98.0
 ;;^UTILITY(U,$J,358.3,41326,2)
 ;;=^5009574
 ;;^UTILITY(U,$J,358.3,41327,0)
 ;;=L40.0^^189^2094^16
 ;;^UTILITY(U,$J,358.3,41327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41327,1,3,0)
 ;;=3^Psoriasis vulgaris
 ;;^UTILITY(U,$J,358.3,41327,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,41327,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,41328,0)
 ;;=L40.1^^189^2094^19
 ;;^UTILITY(U,$J,358.3,41328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41328,1,3,0)
 ;;=3^Pustular Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,41328,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,41328,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,41329,0)
 ;;=L40.9^^189^2094^17
 ;;^UTILITY(U,$J,358.3,41329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41329,1,3,0)
 ;;=3^Psoriasis, unspec
 ;;^UTILITY(U,$J,358.3,41329,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,41329,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,41330,0)
 ;;=L40.3^^189^2094^20
 ;;^UTILITY(U,$J,358.3,41330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41330,1,3,0)
 ;;=3^Pustulosis palmaris et plantaris
 ;;^UTILITY(U,$J,358.3,41330,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,41330,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,41331,0)
 ;;=L40.8^^189^2094^15
 ;;^UTILITY(U,$J,358.3,41331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41331,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,41331,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,41331,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,41332,0)
 ;;=L40.4^^189^2094^18
 ;;^UTILITY(U,$J,358.3,41332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41332,1,3,0)
 ;;=3^Psoriasis,Guttate
 ;;^UTILITY(U,$J,358.3,41332,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,41332,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,41333,0)
 ;;=M72.2^^189^2094^9
 ;;^UTILITY(U,$J,358.3,41333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41333,1,3,0)
 ;;=3^Plantar fascial fibromatosis
 ;;^UTILITY(U,$J,358.3,41333,1,4,0)
 ;;=4^M72.2
 ;;^UTILITY(U,$J,358.3,41333,2)
 ;;=^272598
 ;;^UTILITY(U,$J,358.3,41334,0)
 ;;=M15.9^^189^2094^10
 ;;^UTILITY(U,$J,358.3,41334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41334,1,3,0)
 ;;=3^Polyosteoarthritis,Unspec
 ;;^UTILITY(U,$J,358.3,41334,1,4,0)
 ;;=4^M15.9
 ;;^UTILITY(U,$J,358.3,41334,2)
 ;;=^5010768
 ;;^UTILITY(U,$J,358.3,41335,0)
 ;;=I87.002^^189^2094^13
 ;;^UTILITY(U,$J,358.3,41335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41335,1,3,0)
 ;;=3^Postthrom syndr w/o compl of lft lwr extrem
 ;;^UTILITY(U,$J,358.3,41335,1,4,0)
 ;;=4^I87.002
 ;;^UTILITY(U,$J,358.3,41335,2)
 ;;=^5008028
